Edwards outlines ~11.5% 2026 sales growth and $2.97-$3.05 adjusted EPS
FROM THE WIRE · SEEKINGALPHA.COM
Edwards Lifesciences Q3 2026 earnings: sales beat, raised guidance, stronger TAVR and TMTT growth.
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishRaised guidance and TAVR and TMTT momentum could support expectations for the medtech company's shares.AI-generated summary
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets